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Biocompatibility studies on lanthanum oxide
nanoparticles
B. Brabu,a,b,c S. Haribabu,a,b M. Revathy,a,b S. Anitha,d M. Thangapandiyan,e
K. R. Navaneethakrishnan,a,b C. Gopalakrishnan,a,c S. S. Murugana,b and
T. S. Kumaravel*a,b,f
Lanthanum oxide nanoparticles (LONP), a rare earth metal oxide, have unique properties that make them
a suitable candidate for several biomedical applications. We investigated certain key in vitro and in vivo
biocompatibility endpoints on LONP. LONP were cytotoxic in in vitro assays and predominantly exerted
their action via release of reactive oxygen species. These nanoparticles were neither irritants nor sensi-
tizers in a rabbit model. LONP extracts did not exert any acute systemic toxicity effects in mice. On the
other hand LONP exerted toxicity to the liver following oral administration, suggesting that these particles
are absorbed from the gastrointestinal (GI) tract and deposited in the hepatobiliary system. LONP did not
induce any mutation in the Ames test both in the presence or absence of S-9. These observations provide
a base line biocompatibility and toxicity data on LONP. The current findings will also be useful in defining
standards for nanoparticle containing devices.
Introduction
Lanthanum oxide nanoparticles (LONP), a rare earth metal
oxide, have unique properties that make them a suitable candi-
date for several biomedical applications. Probes coated with
LONP are being developed as implantable sensors of various
molecules such as glucose, phosphate and uric acid.1 In com-
bination with other elements, lanthanum oxide (La2O3) is
being developed as an optical sensing system for measuring
variations in human body temperature.2 Because of its para-
magnetic properties, it is also being developed for the mag-
netic field controlled targeted release of drugs within the
body. La2O3 suppresses bacteria,
3 viruses,4 and fluorescence
dyes,5 selectively binds to several proteins,6 suppresses
calcium channels7 and has light emitting properties.8 While it
is important to note that there are several potential appli-
cations of this nanoparticle in medical device technologies, no
biocompatibility data are currently available on LONP to
assure their safety.
In this manuscript, we investigated biocompatibility of
LONP in line with well established ISO 10993 standards.9
Specifically we investigated cytotoxicity, irritation, sensiti-
zation, acute systemic toxicity and mutagenicity potential of
LONP, which are critical biocompatibility indicators for any
medical devices.9 Several guidance documents on the safety
evaluation of nanomaterials to be used in food/feed, cosmetics
and medical devices have been published by European Food
Safety Authority (EFSA), Scientific Committee on Consumer
Safety (SCCS) and Scientific Committee on Emerging and
Newly Identified Health Risks (SCENIHR) as Scientific Com-
mittees of the European Commission. While International
Organization for Standardization (ISO) ISO 10993 standards
do not give specific guidance on testing the biocompatibility
of materials in the nanoscale range, we adopted these broad
principles and combined them with the usual techniques
employed in nanotoxicology to evaluate the biocompatibility of
LONP. It should be noted that ISO is currently developing gui-
dance on evaluating medical devices containing nanoparticles
(ISO/NP TR 10993-22 under development) and our results may
feed into this process. Also our results will be helpful in evalu-
ating the safety of medical device technologies using LONP as
a raw material. It should be noted that there is an increasing
interest in biocompatibility of nanomaterials.10–12 This work
will further add to the knowledge base of biocompatibility of
nanomaterials.
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Experimental section
Materials and methods
Characterization of lanthanum oxide particles. La2O3 bulk
and nanoparticles were purchased from Ottokemi, Mumbai,
India and Nanoshel USA, respectively. The certificate of analy-
sis from the manufacturer indicated the purity as 99.99%. The
list of impurities were Fe2O3, CaO, SiO2, Cl and others, at con-
centrations of 0.002, 0.002, 0.01, 0.001 and 0.004 ppm, respecti-
vely. These impurities were unlikely to affect the results
obtained. The morphology and size of the particles were
carried out using a High-Resolution Transmission Electron
Microscope (HRTEM-JEOL 3010). The surface charge and the
hydrodynamic diameter of the La2O3 particles were measured
by using a Dynamic Light Scattering analyzer (Nanopartica
analyzer SZ-100). The zeta potential of the samples was
measured at 25 °C and 37 °C to characterize the particles at
room temperature and at physiological temperature.
Cytotoxicity. Cytotoxicity was assessed by the direct contact
method. We used the MTT assay (from the battery of cytotoxi-
city assays described in ISO 10993, part 5)9,13 to assess the
cytotoxicity of LONP. In addition we used assays that reflect
other pathways of cytotoxicity such as the LDH assay (mem-
brane damage), Caspase 3/7 (apoptosis), adenosine triphos-
phate levels (ATP, metabolic competency of cells) and
malondialdehyde levels (MDA, measure of lipid peroxidation).
We also conducted these cytotoxicity assays in the presence of
25 µM ascorbic acid to evaluate whether or not the cytotoxic
effects seen were mediated by the release of reactive oxygen
species (ROS).
Balb/c 3T3 (clone A31) mouse fibroblast cells originally
were obtained from American Type Culture Collection and are
routinely used in our laboratory for cytotoxicity studies. These
cells are cultured in culture flasks containing Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10%
newborn calf serum, 4 mM glutamine and penicillin/strepto-
mycin at 37 ± 1 °C under an atmosphere of 5% CO2. A total of
1 × 105 cells per mL were treated with LONP or La2O3 bulk
materials in 96-well plates and various endpoints assessed as
given in Tables 1 and 2. Commercially available kits were used
to evaluate the MTT assay (Sigma Aldrich, UK), LDH assay
(Roche Applied Sciences, Germany), ATP levels (Sigma Aldrich,
UK) and Caspase 3/7 (Promega BioSciences, USA). Lipid peroxi-
dation was measured in cultures treated with various concen-
trations of LONP quantify the amount of oxidative damage to
phospholipid membranes. For this experiment, the cells were
seeded at 5 × 107 cells per T25 flask. At the end of 24 hours
treatment, 200 µL of the medium supernatant was taken for
lipid peroxidation measurements, and the cultures were
washed thrice with PBS. The cells were then trypsinized and
counted. Around 106 cells were also taken for cellular lipid per-
oxidation measurements. The lipid peroxide samples (MDA)
were stabilised by adding butylated hydroxytoluene and thio-
barbiturate to each sample. The samples were then heated to
95 °C for 1 hour and absorbance was measured at 540 nm. A
similar experiment was repeated with 25 µM ascorbic acid pre-
treatment. The lipid peroxidation experiments were repeated
thrice.
Irritation. All animal studies were carried out following the
approval from the Institutional Animal Ethics Committee. A
skin irritation test was carried out in rabbits as described in
OECD 404. Briefly 0.5 g of LONP was applied to the skin of the
rabbit for 4 hours and the skin was observed for 14 days for
signs of irritation and corrosion.14 Furthermore, an intracuta-
neous test in rabbits was also carried out using polar (saline)
and non-polar (cotton seed oil) extracts (0.2 g mL−1) prepared
at 121 °C for 1 hour.12,13 Rabbits were injected intracuta-
neously with 0.1 mL of the extract and the injected site was
Table 1 Experimental design for cytotoxicity endpoints
Pretreatment Treatmenta Concentrationsb Endpoints tested
Group 1 — La2O3 nanoparticles 0, 20, 60, 100, 200, 400, 600, 800, and 1000 µg mL
−1 1. LDH
Group 2 — La2O3 bulk 0, 20, 60, 100, 200, 400, 600, 800 and 1000 µg mL
−1 2. MTT assay
Group 3 25 µM ascorbic acidc La2O3 nanoparticles 0, 40, 80, 400, 800 and 1000 µg mL
−1 3. ATP levels
4. Caspase 3/7 activation
a Treatment was for 24 hours at 37 °C in a humidified atmosphere of 5% CO2.
b Concentrations for various groups were selected based on
preliminary trials. c Pretreatment was for 3 hours and continued during the 24 hours treatment with test articles.
Table 2 Experimental design for lipid peroxidation experiments
Pretreatment Treatmenta Concentrationsb Endpoints tested
Experiment 1 — La2O3 nanoparticles 0, 40, 80, 400, 800 and 1000 µg mL
−1 Lipid peroxidation
Experiment 2 25 µM ascorbic acidc La2O3 nanoparticles 0, 40, 80, 400, 800 and 1000 µg mL
−1
a Treatment was for 24 hours at 37 °C in a humidified atmosphere of 5% CO2.
b Concentrations for various groups were selected based on
preliminary trials. c Pretreatment was for 3 hours and continued during the 24 hours treatment with the test article.
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observed for 72 hours. Solvents were also injected which
served as negative controls.
Sensitization. Both Beuhler’s (LONP) and guinea pig maxi-
mization tests (GPMT; saline and cotton seed oil extracts of
LONP; 0.2 g mL−1; 121 °C for 1 hour) were used to evaluate
type 4 sensitization reactions. Cinnamic aldehyde served as
positive controls.15,16
Acute toxicity. Acute systemic toxicity studies were carried
out, using saline (IV route) and cotton seed oil (IP route)
extracts (0.2 g mL−1; 121 °C for 1 hour), in mice.17 Also the
acute oral toxicity study of LONP was performed in mice.
Initially two mice were treated with 300 mg per kg body weight
and observed for 14 days. Even though there was no mortality,
animals showed some signs of discomfort and lethargy. There-
fore they were tested with two additional lower doses (50 and
5 mg per kg body weight). Blood samples were taken from
these animals at days 7 and 14 for hematology and biochemis-
try. Gross and histopathology were also carried out. Higher
doses of 2000 mg kg−1 were also tested.
Ames test. The genotoxicity of LONP (extracts as well as the
nanoparticle itself ) was assessed using five strains of the bac-
terium Salmonella Typhimurium (TA98, TA100, TA102, TA1535
and TA1537), following the procedures described by Maron
and Ames.18,19 Appropriate positive control chemicals were
used as shown in Table 3.
Results and discussion
Characterization of lanthanum oxide particles
The morphology and size of the La2O3 particles were measured
by TEM. The morphology of the nanoparticles was spherical
and the mean diameter was approximately 40 nm (see Fig. 1a).
The bulk material seems to be agglomerated and irregular in
shape. The mean size was found to be approximately
600–800 nm in diameter (Fig. 1b).
Furthermore, we also measured the hydrodynamic sizes
of the particles. The observed mean sizes of the particles are
44 nm and 748 nm for nano and bulk, respectively; and their
corresponding size distribution is given in Fig. 2a and b.
The results of the zeta potential suggest that the surfaces of
both particles were positively charged at both temperatures.
The determined values are 7.1 mV (at 25 °C) and 8.1 mV
(at 37 °C) for nanoparticles and 8.2 mV (at 25 °C) and 10.1 mV
(at 37 °C) for bulk particles (Fig. 3).
Fig. 1 TEM image of lanthanum oxide (a) nanoparticles (b) bulk.
Fig. 2 Hydrodynamic size distribution of lanthanum oxide (a) nano-
particles (b) bulk.
Table 3 Positive control chemicals used in the Ames test
Assay Mutagen Solvent Concentration/plate (µg) Salmonella strains
Absence of S-9 Sodium azide Water 1 TA100,TA1535
2 Nitrofluorene DMSO 10 TA98
9 Aminoacridine Ethanol 50 TA1537
Mytomycin C Water 0.5 TA102
Presence of S-9 Benzo(a)pyrene DMSO 5 TA98,TA100
10 TA102,TA1535 & TA1537
Fig. 3 Zeta potentials of La2O3 nanoparticles and bulk materials at
25 °C and 37 °C.
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Treatment of Balb/c 3T3 cells with LONP resulted in a statisti-
cally significant increase in LDH release at concentrations of
400 µg mL−1 (around 38%) and above (around 65%), compared
to that in the untreated cultures (around 4%). No such
increases in LDH release were observed in cultures treated
with bulk materials, when tested up to 1000 µg mL−1 (Fig. 4a).
Pre-treatment of cells with 25 µM ascorbic acid also resulted in
significant increase in LDH release compared to concurrent
untreated controls at 400 µg mL−1 and above, however the
magnitude of response was less compared to the corres-
ponding concentrations without pre-treatment. With ascorbic
acid pre-treatment, the percentages of LDH release at 400, 800
and 1000 µg mL−1 were approximately 23, 24 and 38%, respect-
ively (Fig. 5a). Cultures treated with both LONP and bulk
materials show reduction in cell viabilities as measured by the
MTT assay. Nanoparticles showed statistically significant
decrease in cell viability at 100 µg mL−1 (cell viability of
approximately 52%) and above. With the bulk material, statisti-
cally significant cytotoxicity was observed at 800 and 1000 µg
mL−1 (Fig. 4b). Interestingly, pre-treatment of cultures with
25 µM ascorbic acid eliminated the cytotoxic capacity of LONP
over the entire range of concentrations tested (Fig. 5b). Treat-
ment of cultures with LONP resulted in a small but statistically
significant decrease in cellular ATP at 100 µg mL−1 and above.
No such decrease in ATP levels were observed in cultures
treated with bulk materials (Fig. 4c). Similar to the MTT assay
results, pre-treatment of cultures with 25 µM ascorbic acid also
completely stopped the cellular ATP reductions observed with
nanoparticles over the entire range tested (Fig. 5c). Treatment
of cultures with LONP resulted in activation of Caspase 3/7 at
20 µg mL−1 and above. The activation of Caspase was dose
dependent up to 100 µg mL−1 and then saturated at the same
level. The La2O3 bulk material also activated Caspase 3/7, but
at higher concentrations (800 and 1000 µg mL−1). The acti-
vation of Caspase 3/7 was prevented with pre-treatment of cells
with ascorbic acid (see Fig. 4d and 5d).
A lipid peroxidation product (MDA) was measured in
culture medium as well as in cells following treatment with
LONP. Treatment of cultures with LONP resulted in a signifi-
cant release of MDA in culture medium at concentrations of
400 µg mL−1 and above, whereas cellular MDA levels showed a
significant release at 40 µg mL−1 and above. Pretreatment of
cultures with 25 µM ascorbic acid resulted in a significant pro-
tection against the production of lipid peroxidation (Table 4).
Irritation
Neither the skin irritation test (with LONP) nor the intracuta-
neous test (with extracts) showed any signs of irritation in
rabbits.
Sensitization
Neither the Beuhler’s test (with LONP) nor GPMT (with
extracts) showed any signs of sensitization in guinea pigs. Posi-
tive control chemicals gave a clear positive response.
Fig. 4 Comparison of various cytotoxicity (LDH release, MTT and ATP levels) and apoptosis endpoints between La2O3 nanoparticles and La2O3 bulk
particles. *P < 0.05; **P < 0.01 and ***P < 0.001 compared to 0 µg mL−1.
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The injection of saline(IV) or cotton seed oil (IP) extracts
of LONP did not show any signs of acute systemic toxicity
in mice.
In the acute oral toxicity study, two animals treated with
300 mg kg−1 of LONP did not show any mortality at the end
of the 14 day observation period. Therefore a higher dose of
2000 mg kg−1 was tested in two more animals. Even at this
dose, no mortality was observed. Animals treated with 5 or
50 mg kg−1 showed lethargy and weakness. Gross pathology
showed enlarged hyperemic liver in all animals. Histopathol-
ogy showed several areas of necrosis, infiltration with inflam-
matory cells, Kupffer cell hyperplasia and sinusoidal
distension (see Fig. 6). Alanine transaminase (ALT) and aspar-
tate aminotransferase (AST) were moderately elevated.
Fig. 5 Comparison of various cytotoxicity and apoptosis endpoints between La2O3 nanoparticles and La2O3 bulk particles in the presence of 25 µM
ascorbic acid. *P < 0.05; **P < 0.01 and ***P < 0.001 compared to the corresponding concentration in the absence of ascorbic acid.






La2O3 nanoparticles pre-treated with 25 µM
ascorbic acidb
Culture mediumc Cellularc Culture mediumc Cellularc
0 0.033 ± 0.030 0.043 ± 0.032 0.037 ± 0.008 0.052 ± 0.021
40 0.029 ± 0.011 0.193 ± 0.070*** 0.031 ± 0.019 0.045 ± 0.020
80 0.056 ± 0.016 0.306 ± 0.187*** 0.053 ± 0.009 0.042 ± 0.021
400 0.113 ± 0.009*** 0.550 ± 0.166*** 0.040 ± 0.019 0.053 ± 0.032
800 0.106 ± 0.013*** 0.743 ± 0.218*** 0.177 ± 0.056*** 0.050 ± 0.024
1000 0.183 ± 0.046*** 0.670 ± 0.104*** 0.174 ± 0.038*** 0.251 ± 0.055***
a Treatment was for 24 hours at 37 °C in a humidified atmosphere of 5% CO2.
b Pretreatment with ascorbic acid was for 3 hours and continued
during the 24 hours treatment with the test article. c Lipid peroxidation products from 0.2 mL of culture medium or 106 cells. ***P < 0.001
compared to 0 µg mL−1.
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Positive mutagens used in the present study resulted in a posi-
tive mutagenic response by inducing a multi-fold increase in
the number of His+ revertant colonies over the negative
control. The revertant colony frequencies in the solvent con-
trols fell within the historical negative control ranges. Saline or
cotton seed oil extracts of LONP did not show any mutagenic
response in the Ames test both with and without S-9. Similarly,
LONP also did not show any mutagenic response when tested
up to 1000 µg per plate (both with and without S-9). Higher
doses resulted in severe cytotoxicity.
Discussion
An LONP is being developed as a potential ingredient in many
medical device technologies by different groups around the
world and this is the first report on its biocompatibility. In
this manuscript we investigated key biocompatibility tests that
will be required for all classes of medical devices. It should be
noted that ISO 10993 standard is not specifically designed for
assessing devices containing nanoparticles. Nanoparticles may
have a different toxicity profile because of their small size and
relatively high surface area, making them highly reactive. A
new standard, ISO 10993 part 33 is being developed for this
purpose. The finding from this manuscript would be helpful
in developing standards for nanoparticle containing devices.
Cytotoxicity studies by direct contact showed severe cyto-
toxicity to Balb/c 3T3 cells assessed by MTT, LDH release, ATP
levels and Caspase 3/7 activation assay. By using an antioxi-
dant, we were able to reduce this cytotoxic response,
suggesting that cytotoxicity may in part be due to the release
of ROS. The same phenomenon was observed with MDA levels.
Even though, LONP was cytotoxic by itself, when used in a
medical device technology, it would be firmly bound to some
material and the magnitude of cytotoxic response would be
considerably less. Cytotoxicity of LONP is caused predomi-
nantly by ROS.20 The ROS generated may react with the
cell membrane and intracellular proteins and cause
cytotoxicity.21,22
Two in vivo local tolerance tests were carried out. Neither
the skin irritation test (with LONP) nor the intracutaneous test
(with extracts) showed any signs of irritation in rabbits. Also,
the sensitization studies of Beuhler’s (with LONP) and GPMT
(with extracts) were completely negative. These in vivo dermal
local tolerance results indicate that LONP is not penetrating
the skin in sufficient quantities to produce local cytotoxicity in
skin cells.
The acute systemic toxicity study using polar and non-polar
extracts did not show any signs of toxicity. It is understandable
that LONP are insoluble in both solvents and do not release
lanthanum ions. However, oral administration of LONP
resulted in liver toxicity suggesting that LONP was absorbed
from the gastro intestinal tract via the portal system. This is
contrary to other lanthanum salts that are not readily
absorbed.23 It is interesting to speculate that the small size of
the LONP somehow causes transport to the portal veins and
gets deposited in the liver, where it produces localised cytotoxi-
city. This could be due to the direct physical damage caused
by these nanoparticles or via the release of ROS. Understand-
ing the antioxidant status of the liver is of paramount impor-
tance to understand its mechanisms; and this work is in
progress.
The response of the liver to chemical exposure depends on
the intensity of the insults, the cell population affected, and
the duration of the chemical exposure. A single oral dose of
LONP resulted in severe hepatobiliary damage as seen in histo-
pathology. There were large areas of necrosis especially around
the portal vein suggesting that LONP induced severe necrosis
and inflammation to the hepatocytes surrounding these par-
ticles. These particles were not cleared rapidly as this damage
persisted even after 14 days. ALT and AST were elevated even at
the end of 14 days. These findings suggest that LONP induced
nonspecific toxicity to the hepatobiliary system following oral
administration. This is similar to the observations by Kumari
et al., 201421 who showed similar changes in the liver following
cerium oxide nano and micro particles. Furthermore, subacute
and chronic studies are required to understand the possible
long term toxicity of LONP.
LONP did not show any mutation by the Ames test both in
the presence and absence of S-9. It is commonly believed that
Fig. 6 Optical image of the liver cells (a) control animal – (i) normal hepatic cells, (ii) normal sinusoidal space; (b & c) La2O3 nanoparticles treated
animal – (iii) Kupffer cell, (iv) necrosis, (v) sinusoidal distension, (vi) mononuclear cell infiltration.
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nanoparticles are not easily taken in by prokaryocytes and
therefore the Ames test may not be of value in assessing the
genotoxicity of nanoparticles.24 On the contrary, there are
several published literature suggesting that nanoparticles are
internalised by bacteria and other prokaryotic cells.25–27 There-
fore the notion that nanoparticles will generally be negative in
the Ames test would require further investigations. Further-
more a battery of mutagenicity assays are required to under-
stand the genetic toxicity potential of LONP.
In conclusion, we have generated some key in vitro and
in vivo biocompatibility data on LONP in anticipation of poten-
tial use of this nanoparticle in medical device technologies.
Like many other nanoparticles, LONP also showed non-specific
cytotoxicity, most probably due to its size effect and by releas-
ing ROS. One unexpected finding from this study is that LONP
is rapidly absorbed from the gastrointestinal tract and gets de-
posited in the liver, where it produces persistent nonspecific
hepatoxicity for up to two weeks. Furthermore repeated dose
toxicity studies are underway to understand more about its
uptake.
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